Usana Health Sciences Inc [USNA] stock is trading at $21.93, up 1.53%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The USNA shares have gain 10.48% over the last week, with a monthly amount glided 7.87%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Jefferies downgraded its rating to Underperform on July 07, 2022, and dropped its price target to $53. On April 14, 2022, DA Davidson initiated with a Neutral rating and assigned a price target of $86 on the stock. ROTH Capital started tracking the stock assigning a Buy rating and suggested a price target of $107 on December 17, 2020. Jefferies initiated its recommendation with a Hold and recommended $65 as its price target on August 22, 2019. In a note dated October 25, 2018, Sidoti upgraded an Buy rating on this stock.
Usana Health Sciences Inc [USNA] stock has fluctuated between $18.48 and $38.32 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Usana Health Sciences Inc [NYSE: USNA] shares were valued at $21.93 at the most recent close of the market. An investor can expect a potential return of 59.6% based on the average USNA price forecast.
Analyzing the USNA fundamentals
Usana Health Sciences Inc [NYSE:USNA] reported sales of 912.67M for the trailing twelve months, which represents a growth of 6.72%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at 0.05%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.03 and Total Capital is 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Usana Health Sciences Inc’s Current Ratio is 2.23. In addition, the Quick Ratio stands at 1.46 and the Cash Ratio stands at 1.22. Considering the valuation of this stock, the price to sales ratio is 0.44, the price to book ratio is 0.76 and price to earnings (TTM) ratio is 24.64.
Transactions by insiders
Recent insider trading involved Mulham David Mulham, CHIEF SALES OFFICER, that happened on Dec 10 ’25 when 873.0 shares were sold. CHIEF INFORMATION OFFICER, Benedict Peter completed a deal on Dec 10 ’25 to sell 2673.0 shares. Meanwhile, Officer PETER G BENEDICT bought 2673.0 shares on Dec 10 ’25.
